MRD Status Comparison by 3 Techniques in Patients with Newly Diagnosed Transplant-Eligible MM

2020 Year in Review - Multiple Myeloma - Multiple Myeloma

According to data from the phase 2 FORTE trial, 3 different techniques were analyzed and compared to characterize minimal residual disease (MRD), including positron emission tomography/computed tomography (PET/CT), multiparameter flow cytometry (MFC), and next-generation sequencing (NGS).

Patients with newly diagnosed transplant-eligible multiple myeloma (MM) who were enrolled in the FORTE trial were randomized to arm A (treatment with carfilzomib, lenalidomide, dexamethasone [KRd] induction–autologous stem-cell transplantation [ASCT] intensification–KRd consolidation), arm B (treatment with KRd12), or arm C (treatment with carfilzomib, cyclophosphamide, dexamethasone [KCd] induction–ASCT intensification–KCd consolidation). After these treatments, patients were randomized to treatment with lenalidomide alone or lenalidomide plus carfilzomib.

In patients who achieved very good partial response or better (≥VGPR) before maintenance, 8-color second-generation flow cytometry was used to evaluate MRD in the FORTE trial. In addition, MRD premaintenance was also assessed using NGS when complete response (CR) was achieved. At defined treatment benchmarks of baseline and preceding maintenance, PET/CT scans were performed and the Deauville scores (DS) were applied both to bone marrow uptake and focal lesions (bone marrow score [BMS]; focal lesion score).

A total of 182 patients (of the 474 enrolled in the study) with matched PET/CT and MFC evaluation were included in this analysis. At baseline, focal lesions were present in 92% of patients; median maximum standardized uptake value (SUVmax) was 5.7 (interquartile range, 4.1-8.1). In 11% of patients, extramedullary lesions were present and nearly all patients had increased bone marrow uptake (median SUVmax, 3.5). In 93% of patients, focal lesions ≥4 were present, and in 60% of patients, bone marrow uptake ≥4 was present. Preceding maintenance, PET/CT negativity (defined as DS <4) was present in 80% and 89% in the focal lesions and bone marrow, respectively. After therapy, neither baseline prognostic factors nor PET/CT characteristics were significantly correlated with PET/CT negativity. A total of 95% of patients achieved ≥VGPR; CR was achieved by 67.5% of patients (MFC MRD negativity in 75%). A significant correlation was found between a best CR and bone marrow uptake <4 at premaintenance (P = .013).

In terms of MRD results, the PET/CT and MFC techniques were strongly concordant (Cramér’s V coefficient, 0.76; P <.001; N = 133). In 94% of cases for BMS, PET/CT and MFC were concordant, whereas in 63% of cases for focal lesion score, PET/CT and MFC were concordant. A moderate concordance between PET and NGS (N = 65) was found (Cramér’s V coefficient, 0.39; P <.038). Concordance rates were 84% between PET/CT and NGS for BMS and 67% between PET/CT and NGS for focal lesion score. Substantial concordance was found among the 3 techniques (Krippendorff’s α, 0.60; P = .001).

Several important conclusions came from this analysis. First, in an independent group of patients with newly diagnosed transplant-eligible MM, the applicability and validity of DS criteria for the definition of PET/CT MRD outside the bone marrow were confirmed. Second, best CR and PET/CT negativity were significantly correlated. Third and finally, for focal lesions, PET/CT, MFC, and NGS were complementary and showed good concordance in the bone marrow.

Reference
Abstract and Presentation S207. EHA 2020. June 12, 2020. MRD evaluation by PET/CT according to Deauville criteria combined with bone marrow techniques in newly diagnosed transplant eligible multiple myeloma patients enrolled in the phase II FORTE trial.

Related Items
IKEMA Study: Isatuximab plus Carfilzomib and Dexamethasone in Patients with RRMM
2020 Year in Review - Multiple Myeloma published on February 1, 2021 in Multiple Myeloma
In Patients with RRMM, Idecabtagene Vicleucel, a BCMA-Directed CAR T-Cell Therapy: CRB-401 Study Updates
2020 Year in Review - Multiple Myeloma published on February 1, 2021 in Multiple Myeloma
CARTITUDE-1: In Patients with RRMM, Ciltacabtagene Autoleucel, a BCMA-Directed Chimeric Antigen Receptor T-Cell Therapy
2020 Year in Review - Multiple Myeloma published on February 1, 2021 in Multiple Myeloma
In Patients with RRMM Teclistamab, a BCMA × CD3 Bispecific Antibody: Phase 1 Study Updates
2020 Year in Review - Multiple Myeloma published on February 1, 2021 in Multiple Myeloma
In Patients with RRMM, REGN5458, a BCMA × CD3 Bispecific Monoclonal Antibody, Induces Deep and Durable Responses
2020 Year in Review - Multiple Myeloma published on February 1, 2021 in Multiple Myeloma
APOLLO: In Patients with RRMM, Daratumumab plus Pomalidomide and Dexamethasone versus Pomalidomide and Dexamethasone Alone
2020 Year in Review - Multiple Myeloma published on February 1, 2021 in Multiple Myeloma
Ixazomib, Daratumumab, and Low-Dose Dexamethasone Induction in Frail, Elderly Patients with NDMM
2020 Year in Review - Multiple Myeloma published on February 1, 2021 in Multiple Myeloma
CANDOR Study: Subgroup Analysis of Carfilzomib and Dexamethasone with or without Daratumumab in RRMM
2020 Year in Review - Multiple Myeloma published on February 1, 2021 in Multiple Myeloma
Belantamab Mafodotin Combined with Pomalidomide and Dexamethasone for RRMM: A Dose-Finding Study
2020 Year in Review - Multiple Myeloma published on February 1, 2021 in Multiple Myeloma
DREAMM-2 Study Evaluated Belantamab Mafodotin in Patients with RRMM: Prior Therapy Analysis
2020 Year in Review - Multiple Myeloma published on February 1, 2021 in Multiple Myeloma
Last modified: July 22, 2021